These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12071417)

  • 41. Optimal sample size for a series of pilot trials of new agents.
    Yao TJ; Begg CB; Livingston PO
    Biometrics; 1996 Sep; 52(3):992-1001. PubMed ID: 8805764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Bayesian sequential design with binary outcome.
    Zhu H; Yu Q; Mercante DE
    Pharm Stat; 2017 May; 16(3):192-200. PubMed ID: 28251815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data.
    Vázquez-Polo FJ; Negrín Hernández MA; López-Valcárcel BG
    Health Econ; 2005 Jun; 14(6):545-57. PubMed ID: 15497202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selection of the effect size for sample size determination for a continuous response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD; Peduzzi PN
    Clin Trials; 2016 Jun; 13(3):275-85. PubMed ID: 26928986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sample size requirements and the cost of a randomized clinical trial with repeated measurements.
    Bloch DA
    Stat Med; 1986; 5(6):663-7. PubMed ID: 3823673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bayesian estimation of cost-effectiveness ratios from clinical trials.
    Heitjan DF; Moskowitz AJ; Whang W
    Health Econ; 1999 May; 8(3):191-201. PubMed ID: 10348414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. On sample size and inference for two-stage adaptive designs.
    Liu Q; Chi GY
    Biometrics; 2001 Mar; 57(1):172-7. PubMed ID: 11252594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Approaches for optimal sequential decision analysis in clinical trials.
    Carlin BP; Kadane JB; Gelfand AE
    Biometrics; 1998 Sep; 54(3):964-75. PubMed ID: 9750245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
    Berchialla P; Zohar S; Baldi I
    Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Bayesian approach on sample size calculation for comparing means.
    Wang H; Chow SC; Chen M
    J Biopharm Stat; 2005; 15(5):799-807. PubMed ID: 16078386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Computation of the uniform minimum variance unbiased estimator of a normal mean following a group sequential trial.
    Emerson SS
    Comput Biomed Res; 1993 Feb; 26(1):68-73. PubMed ID: 8444028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Timing of futility analyses for 'proof of concept' trials.
    Lawrence Gould A
    Stat Med; 2005 Jun; 24(12):1815-35. PubMed ID: 15815997
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Key cost drivers of pharmaceutical clinical trials in the United States.
    Sertkaya A; Wong HH; Jessup A; Beleche T
    Clin Trials; 2016 Apr; 13(2):117-26. PubMed ID: 26908540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Designing a cost-effective clinical trial.
    Hornberger JC; Brown BW; Halpern J
    Stat Med; 1995 Oct; 14(20):2249-59. PubMed ID: 8552901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modification of sample size in group sequential clinical trials.
    Cui L; Hung HM; Wang SJ
    Biometrics; 1999 Sep; 55(3):853-7. PubMed ID: 11315017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An investment appraisal approach to clinical trial design.
    Backhouse ME
    Health Econ; 1998 Nov; 7(7):605-19. PubMed ID: 9845254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bayesian assessment of sample size for clinical trials of cost-effectiveness.
    O'Hagan A; Stevens JW
    Med Decis Making; 2001; 21(3):219-30. PubMed ID: 11386629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.